Lung Cancer Edition: Top Headlines for Week of January 9, 2023

In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.

Read the full coverage here:

Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer

Atezolizumab-bevacizumab confers ‘much higher than usual’ survival rates in NSCLC subset

Lung cancer screening leads to more stage I, less stage IV disease incidence

Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup

FDA approves adagrasib for certain adults with non-small cell lung cancer

References:

Johnson ML, et al. Abstract 397600. Presented at: ASCO Plenary Series: December 2022 Session; Dec. 20, 2022.

Press Release

Press Release

Provencio M, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5959.

Vachani A, et al. J Thorac Oncol. 2022;doi:10.1016/j.jtho.2022.08.011.